Related article: Resources for patients
Related article: Resources for patients
Patients intent upon beginning the Marshall Protocol should familiarize themselves with the various resources and Knowledge Base articles available to the them including:
The MP Knowledge Base is partly based on that ongoing longitudinal study supported by the ARF and described below.
Anyone with one or more Auto-immune diagnoses, also anyone with long term medical problems which resist diagnosis, is invited to register.
It is most helpful to the progress of the research, for you then to post when applicable, your decision to postpone, suspend or discontinue use of Olmesartan medoxomil with your reason(s)
where this applies, we also request a brief summary annually to follow up your welfare, in order to make it possible for the research team to analyze outcomes over a ten year period wherever possible.
Support Team members.
The Autoimmunity Research Foundation provides access to a lively online research and support community where the posted experiences of our members have been used to inform directions for new paradigms for recovery from Th1 illness. Member reports of response to various environmental, pharmaceutical and dietary events has also allowed for a more dynamic level of feedback for ongoing research.
In order to join in the conversation, please follow these instructions for How to Register.
Before beginning the Marshall Protocol, patients are required to review the Checklist for starting the Marshall Protocol.
Main article: Safety warnings for the Marshall Protocol
The Marshall Protocol (MP) is a powerful therapy for immune function recovery and must be followed exactly. Every aspect of the MP is designed with a patient's safety in mind. Patients intent on beginning the MP should first ensure that they have completed all the items on the checklist before they begin.
Main article: Working with a physician
Patients on the Marshall Protocol (MP) must work with a licensed physician or other healthcare practitioner, such as a nurse practitioner or physician's assistant. Patients who have the most successful outcomes are proactive and prepared. They internalize the requirements for the MP and, when necessary, work to address any of their physicians' concerns about the treatment. At this point, no doctors are certified in the use of the MP.
Main article: Finding a physician
Related article: Convincing a reluctant physician to prescribe the Marshall Protocol
Generally speaking, it often makes the most sense to work with one's existing doctor when getting on the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis..
Patients who educate themselves, before approaching their doctor, have the most success in getting their doctor to partner with them in their recovery. Especially when they show the initiative to print out the published research and can explain their plan with confidence.
Many patients find that their doctors appreciate when they take the time to provide copies of newly published papers about the protocol. Some patients forward electronic copies (PDFs) to their doctor's email. Some doctors appreciate when their patients provide paper copies with key points highlighted. We recommend you discuss with your doctor how they would prefer to be kept up to date.
Main article: Therapeutic probe
Used in the context of the Marshall Protocol (MP), a therapeutic probeA brief trial of the Marshall Protocol to see if it will generate an immunopathological response. The "gold standard" for testing whether a patient is a good candidate for the MP. refers to a brief trial of the MP, in which patients take regular doses of olmesartan (Benicar) with pulsed, low doses of antibiotics and restrict consumption of vitamin D. The presence of a positive treatment response is taken as an indication that a patient is sick with Th1 diseaseAny of the chronic inflammatory diseases caused by bacterial pathogens. and that the MP is a treatment option for that disease. Although there are other factors and variables, which can strongly suggest the presence of Th1 disease, the therapeutic probe is currently the best method for determining if the MP may be suitable for a patient.
In the context of the therapeutic probe, there are at least three responses or types of responses which indicate that continued treatment with the MP is warranted:
Symptoms which wax and wane in tandem with the every-other-day administration of antibiotics are an especially strong indication of Th1 disease.
It is expected that the way a patient responds to the MP will change over time.
Some patients who have difficulty finding a supportive doctor or have practical reasons to delay taking the MP medications want to do what they can immediately to start the healing process. Eliminating vitamin D (food and supplements) and avoiding natural or bright light exposure are measures that can be followed prior to a doctor's prescription and may make a patient feel better. It may also allow the immune system to begin functioning and killing bacteria, thus provoking an immune system reaction. This will cause an increase in symptoms (perhaps intolerable) and possibly an increase in inflammation to joints and organs not yet protected by olmesartanMedication taken regularly by patients on the Marshall Protocol for its ability to activate the Vitamin D Receptor. Also known by the trade name Benicar. .
Withdrawing vitamin D is encouraged but patients who are not starting olmesartan yet should proceed with caution. All prospective patients, but particularly those who have not yet started olmesartan, should read about a potential withdrawal reaction from light restriction.
— Sallie Q 03.04.2016 adding three sentences before second par on Online research community and modifying what appears to be an error by creating a 'note important' box around the statement commenced with “Important” twice
added to link list *Tools for doing the Marshall Protocol — Sallie Q 24 Jly '15
CureMyTh1.org references removed during transition to closing that site. — Joyful 01.04.2014